The anti-inflammatory drug Dupixent (dupilumab) has generated positive data in a pivotal trial of patients with eosinophilic esophagitis, a chronic, allergic inflammatory disease of the esophagus. Part A of the Phase 3 trial, which enrolled patients 12 years and older, demonstrated significant clinical and anatomic improvements, including the ability to swallow, the developers Sanofi SA and Regeneron Pharmaceuticals Inc announced on 23 May.
